Replies to post #824338 on NorthWest Biotherapeutics Inc (NWBO)

[pqr]

Thanks S1!!!

[GoodGuyBill]

Extrapolate this out to its ultimate end, we are looking at a cancer cure for all tumor-based cancers, imho.

At that same annual meeting, Linda Powers confirmed the first company-sponsored trial using the Kalinski portfolio is already determined. It is an ovarian cancer combination trial with a conditioning regimen, a dendritic cell component, and a third agent. That is CKM + alphaDC1 + checkpoint blockade moving from academic research into NWBO’s own clinical program. She said the lead institutions are “jumping up and down.” A Pittsburgh manufacturing group is being built principally to manufacture Kalinski’s DC products. DCVax-Direct Phase 2 is manufacturing-ready for a below-the-neck solid tumor, IND section partially written, lead institutions in the US and UK on board. Compassionate use is expanding in 2026 to most solid tumor types including DCVax-Direct, not just DCVax-L for brain cancer. These are not plans for someday. These are programs staged and waiting for the key to turn.